EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

The Shared IL ‐12/ IL ‐35 p35 Subunit Is Associated With Heightened Atherogenic Risk in African Patients With Type 2 Diabetes

Die gemeinsame IL-12/IL-35-p35-Untereinheit ist mit erhöhtem atherogenem Risiko bei afrikanischen Patient:innen mit Typ-2-Diabetes assoziiert

Tawanda M Nyambuya iD, Edwig Shingenge iD, Fransina Ndevahoma, Bongani B Nkambule

Endocrinology, Diabetes & Metabolism · 2026-09 · 9 (5)

DOI: 10.1002/edm2.70306 ↗

Auf einen Blick

Bei 80 Patient:innen mit Typ-2-Diabetes war ein hoher IL-12/IL-35-p35-Spiegel mit ungünstigeren Glukose- und Atherogenitätsmarkern verbunden. Auch die Triglycerid-/HDL-Ratio und TyG waren höher.

Fragestellung

Besteht bei Typ-2-Diabetes ein Zusammenhang zwischen zirkulierendem IL-12/IL-35-p35 und metabolischen sowie atherogenen Risikomarkern?

Methode

Querschnittstudie mit 80 Patient:innen mit Typ-2-Diabetes; Einteilung per Median-Split in Low- und High-IL-12/IL-35-p35-Gruppe; Laborparameter und IL-12/IL-35-p35 per ELISA gemessen.

Ergebnisse

High-IL-12/IL-35-p35 war mit höherer Nüchternglukose (p = 0,0318), Triglyceriden, Triglycerid/HDL-Ratio, TyG und AIP assoziiert (je p < 0,0001). AUC für hohes AIP: 0,79 (95 %-KI 0,68–0,89); für erhöhten TyG: 0,78 (95 %-KI 0,63–0,93).

Schlussfolgerung der Autor:innen

Erhöhtes zirkulierendes IL-12/IL-35-p35 bei Typ-2-Diabetes ist mit suboptimaler Glukosekontrolle und ausgeprägter Atherogenität verbunden und könnte einen Immunungleichgewichtsmarker darstellen.

Kernaussagen

  • High-IL-12/IL-35-p35 ging mit ungünstigeren Stoffwechselmarkern einher.
  • AIP und TyG wurden durch IL-12/IL-35-p35 gut diskriminiert.
  • Die Autor:innen sehen p35 als möglichen Marker für Immunungleichgewicht.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Journal article in Endocrinology, Diabetes & Metabolism, published online on 2026-09-04. Written by Tawanda M Nyambuya and 3 co-authors. Institution: Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Sou…. Major MEDLINE topics: Diabetes Mellitus, Type 2, Atherosclerosis, Interleukin-12, Interleukins. 47 references. The full text is freely available (open access, CC BY 4.0). Funded by: Namibia University of Science and Technology.

Auf einen BlickAbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

Interleukin (IL)‐12 and IL‐35 are heterodimeric cytokines that share the p35 subunit and have opposing inflammatory roles. Dysregulated IL‐12/IL‐35 p35 may reflect an imbalance between pro‐ and anti‐inflammatory pathways linking metabolic dysfunction to cardiovascular risk in type 2 diabetes (T2D). However, the clinical significance of circulating IL‐12/IL‐35 p35 levels remains unclear. This study investigated the association between IL‐12/IL‐35 p35 levels and metabolic and atherogenic risk markers in T2D.

Methods

This cross‐sectional study stratified 80 patients with T2D into Low and High IL‐12/IL‐35 p35 groups ( n = 40/group) using a median split of plasma IL‐12/IL‐35 p35 (18.48 pg/mL). Laboratory parameters were measured using standard methods, and IL‐12/IL‐35 p35 concentrations were quantified by Enzyme Linked Immunosorbent Assay.

Results

Patients with High IL‐12/IL‐35 p35 had significantly elevated fasting glucose ( p = 0.0318), triglycerides ( p < 0.0001), triglyceride/HDL ratio ( p < 0.0001), Triglyceride‐Glucose (TyG) ( p < 0.0001), and atherogenic index of plasma (AIP) ( p < 0.0001). Circulating IL‐12/IL‐35 p35 levels positively correlated with triglycerides, AIP, Trig/HDL ratio and TyG index (all p < 0.0001), and negatively correlated with HDL ( p = 0.0466). In the multiple linear regression analysis, IL‐12/IL‐35 p35 levels and TyG index (all p < 0.05) independently predicted atherogenicity after adjusting for glycaemic control. Receiver operating characteristic analysis demonstrated that IL‐12/IL‐35 p35 discriminated participants with high‐risk AIP (AUC = 0.79, 95% CI: 0.68–0.89, p < 0.0001) and elevated TyG index (AUC = 0.78, 95% CI: 0.63–0.93, p = 0.0147).

Conclusion

Elevated circulating IL‐12/IL‐35 p35 in T2D is associated with suboptimal glucose control and pronounced atherogenicity, suggesting altered activity within this immunoregulatory axis. These findings highlight the shared p35 subunit as a marker of immune imbalance and support its potential utility in identifying heightened atherogenic risk in T2D beyond the traditional markers. Future studies should directly quantify intact IL‐12 and IL‐35 to elucidate their individual contributions to the alteration of this immunoregulatory axis.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2AtherosclerosisInterleukin-12InterleukinsInterleukin-12 Subunit p35HumansFemaleMaleMiddle AgedCross-Sectional StudiesBiomarkersAdultAgedRisk FactorsBlood Glucose

Author keywords

IL‐12/IL‐35 axisT2Datherogenicityinflammationp35 subunit

Substances

Interleukin-12interleukin-35, humanInterleukinsInterleukin-12 Subunit p35BiomarkersBlood Glucose

Authors and institutions

  • Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Health Sciences, Faculty of Health, Applied Sciences and Natural Resources, Namibia University of Science and Technology, Windhoek, Namibia.
  • School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

ORCID profiles: Tawanda M Nyambuya, Edwig Shingenge

Funding

  • Namibia University of Science and Technology

Cite

APA

Nyambuya, T. M., Shingenge, E., Ndevahoma, F., & Nkambule, B. B. (2026). The Shared IL ‐12/ IL ‐35 p35 Subunit Is Associated With Heightened Atherogenic Risk in African Patients With Type 2 Diabetes. Endocrinology, Diabetes & Metabolism, 9(5). https://doi.org/10.1002/edm2.70306

Vancouver

Nyambuya TM, Shingenge E, Ndevahoma F, Nkambule BB. The Shared IL ‐12/ IL ‐35 p35 Subunit Is Associated With Heightened Atherogenic Risk in African Patients With Type 2 Diabetes. Endocrinology, Diabetes & Metabolism. 2026;9(5). doi:10.1002/edm2.70306

BibTeX
@article{Nyambuya2026,
  author = {Nyambuya, Tawanda M and Shingenge, Edwig and Ndevahoma, Fransina and Nkambule, Bongani B},
  title = {The Shared IL ‐12/ IL ‐35 p35 Subunit Is Associated With Heightened Atherogenic Risk in African Patients With Type 2 Diabetes},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  volume = {9},
  number = {5},
  doi = {10.1002/edm2.70306}
}
Start for free →